Business Wire (Fri, 7:00AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
422 people get SLXP articles and Market Currents by email alert.
Get email alerts on SLXP »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Business Wire (May 9, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 25, 2013)
-
-
Business Wire (Feb 28, 2013)
-
Business Wire (Feb 25, 2013)
-
-
Business Wire (Feb 14, 2013)
-
Keep Your Eye On Earnings This WeekDavid Brown • Tue, Jan 22 -
Business Wire (Jan 2, 2013)
-
Business Wire (Nov 9, 2012)
-
Business Wire (Nov 7, 2012)
-
Business Wire (Nov 7, 2012)
-
Business Wire (Oct 24, 2012)
To learn more about Seeking Alpha Pro, click here.
-
-
Salix Pharmaceuticals: Hot Biotech For Long-Term GrowthDavid Zanoni • Fri, Aug 10, 2012 -
What's It Going To Take To Get Salix Cheap?Stephen Simpson • Wed, Feb 29, 2012
-
-
Salix Pharmaceuticals: Poised To ProsperGeorge Liu • Thu, Dec 22, 2011 -
Neutral on SalixZacks Investment Research • Thu, Mar 17, 2011 -
Salix Pharmaceuticals: Q4 Beats but Outlook DisappointsZacks Investment Research • Wed, Mar 10, 2010
-
Salix Pharmaceuticals Focuses on Label ExpansionZacks Investment Research • Sun, Mar 7, 2010
-
-
Salix Pharma Continues to Rise in Anticipation of FDA DecisionM. E. Garza • Sun, Sep 6, 2009
-
-
-
Keep Your Eye On Earnings This WeekDavid Brown • Tue, Jan 22
-
5 Profitable Mid-Cap Stocks Loaded With CashZetaKap • Wed, Sep 26, 2012 -
-
-
3 Highly Liquid Drugmakers Undervalued By EPS TrendsKapitall • Fri, Aug 24, 2012 -
8 Highly Liquid Healthcare Stocks Undervalued By EPS TrendsKapitall • Thu, Aug 23, 2012
-
-
7 Profitable Healthcare Stocks That Analysts LoveZetaKap • Fri, Aug 10, 2012
-
-
2 Pharma Stocks To Consider In The Wake Of An FDA RejectionMatt Schilling • Mon, Jul 30, 2012 -
-
-
-
-
-
-
-
-
Salix Pharmaceuticals Ltd Q3 2009 Earnings Call TranscriptMon, Nov 9, 2009
-
Salix Pharmaceuticals, Ltd. Q4 2008 Earnings Call TranscriptTue, Mar 10, 2009
-
Salix Pharmaceuticals, Ltd. Q3 2008 Earnings Call TranscriptFri, Nov 21, 2008
-
Salix Pharmaceuticals Ltd. Q2 2008 Earnings Call TranscriptMon, Aug 4, 2008
-
Salix Pharmaceuticals Ltd. Q1 2008 Earnings Call TranscriptTue, May 6, 2008
-
Salix Pharmaceuticals Ltd. Q4 2007 Earnings Call TranscriptMon, Mar 3, 2008
-
Salix Pharmaceuticals Q3 2007 Earnings Call TranscriptTue, Nov 6, 2007
-
Business Wire (Fri, 7:00AM)
-
Business Wire (May 9, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 25, 2013)
-
Business Wire (Feb 28, 2013)
-
Business Wire (Feb 25, 2013)
-
Business Wire (Feb 14, 2013)
-
Business Wire (Jan 2, 2013)
-
Business Wire (Nov 9, 2012)
-
Business Wire (Nov 7, 2012)
-
Business Wire (Nov 7, 2012)
-
Business Wire (Oct 24, 2012)
-
Business Wire (Oct 19, 2012)
-
Business Wire (Sep 5, 2012)
-
Business Wire (Sep 5, 2012)
-
at CNBC.com (Aug 9, 2012)
-
Business Wire (Aug 8, 2012)
SLXP vs. ETF Alternatives
Company Description
Salix Pharmaceuticals, Ltd., a Delaware corporation, is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. Our strategy is... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, May 10, 8:58 AM More on Progenics' (PGNX) earnings: Relistor sales rise 47% Q/Q and fall 37% Y/Y, as royalties were $1.2M in Q1 compared to $1.8M in Q1 2012. Data from Salix (SLXP) (which said on its CC that prescription growth increased 52% Y/Y) including the regional breakdown, shows Relistor net sales of $6.7M in the U.S. and $1M outside the country. SLXP also notes that it believes a path forward for the drug (in terms of expanding its indications) "could be reached with the FDA" this year. PGNX shares +21% premarket. (PR) Comment! [Healthcare, On the Move]
- Friday, May 10, 7:41 AM Salix Pharmaceuticals' (SLXP) Q1 "was not a miss," Jefferies insists, noting some confusion about how consensus is constructed. "Regardless, Xifaxan strength continues and this is the key value driver. SLXP remains one of the best growth stories in Spec Pharma, and we would be buyers especially on any weakness." Shares were -0.3% AH, but are +33.8% YTD. Comment! [Earnings, Healthcare, Quick Ideas]
- Thursday, May 9, 4:19 PM Salix Pharmaceuticals (SLXP): Q1 EPS of $0.63 misses by $0.04. Revenue of $202.6M misses by $3.34M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, May 9, 12:10 AM Notable earnings after Thursday’s close: AGO, AIRM, AL, ALIM, ANAC, ASYS, AUQ, BCEI, BID, BPZ, CALL, CPE, DAR, EGY, ET, FTK, FXEN, GXP, KTOS, LLNW, MBI, MCP, MDRX, MDVN, NGVC, NVDA, OPTR, PANL, PCLN, PDLI, PSA, RNDY, SF, SLXP, SQNM, TNGO, UBNT, ZGNX Comment! [Earnings]
- Wednesday, May 8, 5:35 PM Notable earnings after Thursday’s close: AGO, AIRM, AL, ALIM, ANAC, ASYS, AUQ, BCEI, BID, BPZ, CALL, CPE, DAR, EGY, ET, FTK, FXEN, GXP, KTOS, LLNW, MBI, MCP, MDRX, MDVN, NGVC, NVDA, OPTR, PANL, PCLN, PDLI, PSA, RNDY, SF, SLXP, SQNM, TNGO, UBNT, ZGNX Comment! [Earnings]
- Thursday, February 28, 4:28 PM Salix Pharmaceuticals (SLXP): Q4 EPS of $0.81 beats by $0.03. Revenue of $198.1M misses by $1.31M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, February 28, 12:10 AM Notable earnings after Thursday’s close: AIRM, AL, ALSK, BID, CLNE, CPNO, CRM, DECK, DRH, ENDP, GPS, GXP, HTGC, JOE, KOG, KYAK, MCP, MDR, MDVN, MENT, MTZ, MXWL, NGD, NOG, OPTR, OVTI, PANW, RNDY, RST, SD, SLXP, SONS, SPLK, SSRI, TEG, TESO, UHS, WR, XTEX, YOKU Comment! [Earnings]
- Wednesday, February 27, 5:35 PM Notable earnings after Thursday’s close: AIRM, AL, ALSK, BID, CLNE, CPNO, CRM, DECK, DRH, ENDP, GPS, GXP, HTGC, JOE, KOG, KYAK, MCP, MDR, MDVN, MENT, MTZ, MXWL, NGD, NOG, OPTR, OVTI, PANW, RNDY, RST, SD, SLXP, SONS, SPLK, SSRI, TEG, TESO, UHS, WR, XTEX, YOKU 1 Comment [Earnings]
- Monday, December 31, 2012, 3:37 PM Salix Pharmaceutical's (SLXP +1.4%) moves up after the FDA approves Fulyzaq to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy. The drug, which is the first of its kind to relieve diarrhea in AIDS patients and is a common reason why patients discontinue or switch their antiretroviral therapies, is distributed by SLXP under license from Napo Pharmaceuticals. Comment! [Healthcare, On the Move]
- Thursday, November 8, 2012, 3:42 PM Salix Pharmaceuticals (SLXP +7.5%) gets a pop today after its Q3 EPS came in well ahead of expectations and the drug developer raised its FY12 profit guidance for the third time this year. Sales of its key antibiotic drug Xifaxan jumped 43%, leaving analysts estimates in the dust. The company now expects an FY12 EPS of $3.13 on revenues of $735M, above the Street estimate of $2.89 on revenues of $739M. Comment! [Healthcare, Earnings, On the Move]
- Wednesday, November 7, 2012, 4:41 PM Salix Pharmaceuticals (SLXP): Q3 EPS of $0.95 beats by $0.25. Revenue of $185.1M (+26.6% Y/Y) misses by $2M. Shares +8.4% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
- Wednesday, November 7, 2012, 12:10 AM Notable earnings after Wednesday’s close: ARAY, ATO, ATVI, AWK, BONE, CBS, CLR, CODI, CPE, CPNO, CTL, CXO, ETE, ETP, EXEL, FTK, GMXR, GSS, HIMX, HNSN, ITMN, KGC, MAKO, MBI, MDLZ, MNST, MWE, NQ, OAS, ONTY, OSUR, PAAS, PANL, PRI, PRU, QCOM, SGEN, SLXP, SNTS, SRZ, SSRI, SXL, TCAP, TIE, TS, WFM Comment! [Earnings]
- Tuesday, November 6, 2012, 5:35 PM Notable earnings after Wednesday’s close: ARAY, ATO, ATVI, AWK, BONE, CBS, CLR, CODI, CPE, CPNO, CTL, CXO, ETE, ETP, EXEL, FTK, GMXR, GSS, HIMX, HNSN, ITMN, KGC, MAKO, MBI, MDLZ, MNST, MWE, NQ, OAS, ONTY, OSUR, PAAS, PANL, PRI, PRU, QCOM, SGEN, SLXP, SNTS, SRZ, SSRI, SXL, TCAP, TIE, TS, WFM Comment! [Earnings]
- Wednesday, September 5, 2012, 8:32 AM The FDA delays a decision on Salix's (SLXP) crofelemer drug for treating HIV-related diarrhea, with a ruling now expected by the end of Q1 2013. Talks between Salix and the FDA are focusing on the production and control of the crofelemer active pharmaceutical ingredient. Episodic or chronic diarrhea affects ~40% of the U.S.'s 1.2M HIV/AIDS sufferers. Comment! [Healthcare]
- Thursday, August 9, 2012, 1:35 PM Salix Pharmaceuticals (SLXP +2%) trades higher after beating bottom line Q2 estimates yesterday. Net profit rose 4.6% as the drug developer saw continued strength in sales of its Xifaxan tablets. The company also raised its FY12 outlook to $2.86 per share, up from its previous view of $2.59 a share, reflecting its March placement of $690M in senior notes. Comment! [Healthcare, Earnings, On the Move]
- Wednesday, August 8, 2012, 5:28 PM Salix Pharmaceuticals (SLXP): Q2 EPS of $0.79 beats by $0.25. Revenue of $181M (+36% Y/Y) in-line. Shares +9.4% AH. (PR) Comment! [Earnings, Healthcare, On the Move]